Affinity DataKd: 1.40E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 200nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 3.60E+3nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 130nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 40nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 130nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 0.190nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 19nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 200nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
Affinity DataKd: 7nMAssay Description:Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged STK4 (unknown origin) expressed in baculovirus infected Sf9 insect cells i...More data for this Ligand-Target Pair
Affinity DataKd: 4nMAssay Description:Binding affinity to recombinant full-length N-terminal His-FLAG-GST-tagged STK4 (unknown origin) expressed in baculovirus infected Sf9 insect cells i...More data for this Ligand-Target Pair
Affinity DataKd: 147nMAssay Description:Binding affinity to recombinant N-terminal His6-tagged human STK4 (43 to 431 residues) expressed in Escherichia coli assessed as dissociation constan...More data for this Ligand-Target Pair
Affinity DataKd: 158nMAssay Description:Binding affinity to recombinant N-terminal His6-tagged human STK4 (43 to 431 residues) expressed in Escherichia coli assessed as dissociation constan...More data for this Ligand-Target Pair
Affinity DataKd: 2.20E+3nMAssay Description:Average Binding Constant for STK4; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
Affinity DataKd: 0.200nMAssay Description:Average Binding Constant for STK4; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
Affinity DataKd: 220nMAssay Description:Average Binding Constant for STK4; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
Affinity DataKd: 100nMAssay Description:Average Binding Constant for STK4; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
Affinity DataKd: 3.90E+3nMAssay Description:Average Binding Constant for STK4; NA=Not Active at 10 uMMore data for this Ligand-Target Pair
Affinity DataKd: 240nMAssay Description:Binding affinity to wild-type human full length MST1 (M1 to F487 residues) expressed in bacterial expression system by Kinomescan methodMore data for this Ligand-Target Pair
Affinity DataKd: 1nMAssay Description:Binding affinity to recombinant STK4 (unknown origin) assessed as dissociation constant by DSF assayMore data for this Ligand-Target Pair













































